Vanguard Group Inc. Boosts Stock Position in Vera Therapeutics, Inc. (NASDAQ:VERA)

Vanguard Group Inc. lifted its position in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 9.3% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 1,574,390 shares of the company's stock after purchasing an additional 134,125 shares during the period. Vanguard Group Inc. owned about 3.54% of Vera Therapeutics worth $21,585,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently made changes to their positions in VERA. Tower Research Capital LLC TRC boosted its holdings in Vera Therapeutics by 810.4% in the first quarter. Tower Research Capital LLC TRC now owns 4,834 shares of the company's stock valued at $38,000 after acquiring an additional 4,303 shares in the last quarter. Ameritas Investment Partners Inc. boosted its holdings in Vera Therapeutics by 163.1% in the second quarter. Ameritas Investment Partners Inc. now owns 2,792 shares of the company's stock valued at $45,000 after acquiring an additional 1,731 shares in the last quarter. UBS Group AG purchased a new position in Vera Therapeutics during the first quarter valued at $47,000. Royal Bank of Canada lifted its position in Vera Therapeutics by 94.8% during the second quarter. Royal Bank of Canada now owns 3,339 shares of the company's stock valued at $54,000 after buying an additional 1,625 shares during the period. Finally, Amalgamated Bank lifted its position in Vera Therapeutics by 26.0% during the third quarter. Amalgamated Bank now owns 4,189 shares of the company's stock valued at $57,000 after buying an additional 864 shares during the period. Institutional investors own 99.21% of the company's stock.

Insider Buying and Selling

In related news, SVP Joseph R. Young sold 5,714 shares of the business's stock in a transaction that occurred on Wednesday, April 10th. The stock was sold at an average price of $40.00, for a total value of $228,560.00. Following the transaction, the senior vice president now directly owns 53,171 shares of the company's stock, valued at approximately $2,126,840. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, Director Maha Katabi sold 81,009 shares of the stock in a transaction on Thursday, March 21st. The stock was sold at an average price of $44.20, for a total transaction of $3,580,597.80. Following the sale, the director now owns 3,547,437 shares in the company, valued at approximately $156,796,715.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Joseph R. Young sold 5,714 shares of the stock in a transaction on Wednesday, April 10th. The shares were sold at an average price of $40.00, for a total value of $228,560.00. Following the sale, the senior vice president now owns 53,171 shares in the company, valued at approximately $2,126,840. The disclosure for this sale can be found here. In the last three months, insiders have sold 526,551 shares of company stock valued at $21,533,345. Corporate insiders own 22.60% of the company's stock.

Wall Street Analysts Forecast Growth

VERA has been the subject of several recent analyst reports. HC Wainwright reaffirmed a "buy" rating and issued a $25.00 price target on shares of Vera Therapeutics in a research report on Wednesday, December 27th. Cantor Fitzgerald initiated coverage on Vera Therapeutics in a research report on Monday, January 8th. They issued an "overweight" rating for the company. Oppenheimer initiated coverage on Vera Therapeutics in a research report on Thursday, January 25th. They issued an "outperform" rating and a $26.00 price target for the company. Guggenheim reaffirmed a "buy" rating and issued a $56.00 price target on shares of Vera Therapeutics in a research report on Friday, April 5th. Finally, Raymond James upgraded Vera Therapeutics from an "outperform" rating to a "strong-buy" rating and lifted their price objective for the stock from $29.00 to $37.00 in a report on Friday, January 26th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $32.29.

Vera Therapeutics Price Performance

NASDAQ VERA traded down $0.85 during trading hours on Friday, reaching $47.97. The company's stock had a trading volume of 2,166,265 shares, compared to its average volume of 1,056,250. The firm's 50-day moving average price is $43.39 and its 200-day moving average price is $25.12. The company has a quick ratio of 7.71, a current ratio of 7.71 and a debt-to-equity ratio of 0.49. Vera Therapeutics, Inc. has a 1 year low of $6.05 and a 1 year high of $50.78. The company has a market capitalization of $2.61 billion, a price-to-earnings ratio of -20.95 and a beta of 1.05.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.